VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
TRDA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
TRDAEntrada Therapeutics, Inc.
$5.03$195M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. TRDA
  4. Financial Ratios

Entrada Therapeutics, Inc. (TRDA) Financial Ratios

Latest Ratios: P/E Ratio -1.3x · EV/EBITDA N/A · ROE -39.1%. (2019–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

TRDA Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Market Cap$195M$425M$674M$499M$423M$535M——
Enterprise Value$156M$386M$632M$499M$404M$243M——
P/E Ratio →-1.32—10.29—————
P/S Ratio49.1016.733.203.87————
P/B Ratio0.681.391.572.061.991.79——
P/FCF———3.72————
P/OCF———3.57————

P/E links to full P/E history page with 30-year chart

TRDA EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
EV / Revenue—15.183.003.87————
EV / EBITDA——12.45—————
EV / EBIT——9.5141.42————
EV / FCF———3.72————

TRDA Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Gross Margin83.9%83.9%100.0%100.0%————
Operating Margin-613.7%-613.7%22.3%-2.5%————
Net Profit Margin-565.5%-565.5%31.1%-5.2%————

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
ROE-39.1%-39.1%19.6%-2.9%-37.0%-39.8%——
ROA-31.8%-31.8%13.2%-1.9%-33.9%-29.3%-85.9%-25.5%
ROIC-35.8%-35.8%11.2%-1.1%-72.6%———
ROCE-37.2%-37.2%11.8%-1.2%-36.8%-30.1%-94.4%-72.5%

TRDA Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Debt / Equity0.170.170.140.280.12———
Debt / EBITDA——1.17—————
Net Debt / Equity—-0.13-0.100.00-0.09-0.97——
Net Debt / EBITDA——-0.83—————
Debt / FCF———0.00————
Interest Coverage————-34.95———

Net cash position: cash ($90M) exceeds total debt ($51M)

TRDA Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Current Ratio12.5312.5311.152.339.5544.4611.899.08
Quick Ratio12.5312.5311.152.339.5544.4611.899.08
Cash Ratio12.0912.0910.642.228.5943.3211.628.77
Asset Turnover—0.070.400.27————
Inventory Turnover————————
Days Sales Outstanding—37.006.3716.63————

TRDA Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Dividend Yield————————
Payout Ratio————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Earnings Yield——9.7%—————
FCF Yield———26.9%————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%——
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%——
Shares Outstanding—$41M$39M$33M$31M$31M$31M$1M

Key Metrics

Growth RegimeContracting
ProfitabilityWeak
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Runway vs. immaterial revenue base

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Asset Discount Masks Revenue Evaporation

TRDA trades at 0.65x book yet 7.39x sales, a divergence suggesting the market is pricing the balance sheet, not the business. With trailing P/E at -1.39 and no EV/EBITDA observable, valuation rests entirely on residual assets rather than earning power, per current market data.

The 7.39x price-to-sales multiple looks superficially in line with pre-commercial biotech peers, but because TRDA's quarterly revenue has collapsed to under $1M, this ratio reflects an eroding denominator rather than a rich growth premium; investors should treat it as near-meaningless. The 0.65x P/B discount to peers such as NTLA (2.15x) and BEAM (2.30x) may indicate the market prices TRDA's cash-heavy balance sheet with a governance or durability haircut rather than assigning franchise value to its intracellular therapeutic platform.

Returns Swing From Compounder to Destroyer

ROIC collapsed from +13.9% in 2024Q2 to -15.8% in 2026Q2, with ROE following the same path from +15.7% to -17.0%, based on Entrada's reported quarterly ratio disclosures. The reversal appears episodic rather than cyclical, tied to a one-time revenue event.

The 2024 profitability spike coincided with the $94.7M revenue quarter that has not recurred, so the historical ROIC peak should not be read as evidence of a durable moat; on the current cost structure of roughly $46M quarterly operating expense against sub-$1M revenue, every dollar of capital deployed is producing negative returns. The persistence of double-digit negative ROIC across eight of ten quarters suggests the business is decaying capital rather than compounding it, and any recovery thesis hinges on pipeline economics that the ratio data cannot confirm.

Receivables Lengthen as Sales Vanish

DSO ballooned from 8 days in 2024Q4 to 157 days in 2026Q2 while asset turnover flatlined at 0.00, per Entrada's quarterly ratio reporting. Longer collection periods against a shrinking revenue base imply receivable quality and recoverability warrant closer diligence.

A 157-day DSO alongside immaterial revenue suggests the receivables balance is stale relative to current billings, potentially representing milestone or royalty amounts with collection timing outside management's control; analysts should test this against allowance disclosures. The near-zero asset turnover confirms the company's $298.9M asset base is effectively idle in commercial terms, meaning efficiency ratios offer no offset to the burn — the assets are being consumed, not deployed.

High Current Ratio Belies Short Runway

TRDA's current and quick ratios both stand at 10.89 in 2026Q2, identical figures that signal almost no inventory dependence, yet against roughly $42M of quarterly operating losses this liquidity buffer appears to translate to only two-to-three quarters of runway, as inferred from reported financial statements.

The absence of a gap between current and quick ratios indicates TRDA's current assets are almost entirely cash and receivables, which is favorable for liquidation quality but means the buffer has no operational ballast. The stress test is straightforward: with a debt-to-equity ratio of just 0.21 and modest absolute debt near $48.5M, refinancing is not the binding constraint — equity issuance on dilutive terms appears more likely, and the falling cash base should be monitored against the burn rate disclosed in cash flow filings.

Low Leverage Offers Limited Signal

Debt-to-equity eased from 0.25 in 2024Q1 to 0.21 in 2026Q2, with interest coverage unavailable across all periods presented, according to Entrada's quarterly disclosures. Minimal leverage provides strategic flexibility but says little about creditworthiness when operations consume cash at the current pace.

Because the D/E ratio of 0.21 sits below most listed genetic-medicine peers — NTLA at 0.14 is comparable, but ARWR at 0.73 and EDIT at 2.81 carry more debt — TRDA's low leverage appears to reflect a choice enabled by prior capital raises rather than superior cash generation, and the declining absolute debt load is consistent with scheduled repayment from a shrinking asset base. The absence of coverage and D/EBITDA data means solvency cannot be assessed conventionally; investors should instead anchor on cash runway and covenant terms in debt filings.

Price-to-Book Is the Trap Multiple Here

The 0.65x P/B is the ratio most likely to mislead on TRDA, since its book value is almost entirely funded shareholder cash rather than accumulated operating earnings, per reported balance sheets. A sub-1x reading on such a base reflects run-off risk, not value.

In biotechnology platforms, book value accumulates from successive equity raises, so a low P/B typically signals the market's expectation that capital will be burned before it earns — precisely the dynamic TRDA's -17% ROE and persistent negative FCF margins illustrate, rather than a classic deep-value setup. A more informative alternative is enterprise value relative to remaining cash and pipeline stage, or a scenario-weighted value of partnership and milestone potential, which would force explicit assumptions about a revenue base that has already contracted by over 99% from its 2024 peak.

Download Financial Ratios Data

Includes 30+ ratios · 7 years · Updated daily

Consensus & Technical Research Suite
Open TRDA Terminal

TRDA Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

TRDA — Frequently Asked Questions

Quick answers to the most common questions about buying TRDA stock.

What is Entrada Therapeutics, Inc.'s P/E ratio?

Entrada Therapeutics, Inc.'s current P/E ratio is -1.3x. The historical average is 10.3x.

What is Entrada Therapeutics, Inc.'s ROE?

Entrada Therapeutics, Inc.'s return on equity (ROE) is -39.1%. The historical average is -19.9%.

Is TRDA stock overvalued?

Based on historical data, Entrada Therapeutics, Inc. is trading at a P/E of -1.3x. Compare with industry peers and growth rates for a complete picture.

What are Entrada Therapeutics, Inc.'s profit margins?

Entrada Therapeutics, Inc. has 83.9% gross margin and -613.7% operating margin.